Publications

August 2018 (Revised February 2019)
Case

Alvogen: Scaling Entrepreneurship

By: Daniel Isenberg, William R. Kerr and Alexis Brownell

Keywords: Pharmaceutical Companies; Scaling; Generic Drugs; Entrepreneurship; Leadership; Pharmaceutical Industry; Asia; Europe; United States; Iceland

November 2022 (Revised April 2024)
Case

Martine Rothblatt and United Therapeutics: A Series of Implausible Dreams

By: Debora L. Spar and Julia M. Comeau

In 1990, satellite expert and Sirius XM founder Martine Rothblatt was determined to save the life of her seven-year-old daughter, Jenesis, who was diagnosed with a terminal illness called Pulmonary Arterial Hypertension (PAH). At the time, there was little medication... View Details

Keywords: Pharmaceutical Companies; Technological And Scientific Innovation; Organ Donation; Health Care and Treatment; Health Disorders; Innovation and Invention; Pharmaceutical Industry; Pharmaceutical Industry; United States; District of Columbia

November 2024
Teaching Note

Martine Rothblatt and United Therapeutics: A Series of Implausible Dreams

By: Debora L. Spar and Julia M. Comeau

Teaching Note for HBS Case No. 323-039. In 1990, satellite expert and Sirius XM founder Martine Rothblatt was determined to save the life of her seven-year-old daughter, Jenesis, who was diagnosed with a terminal illness called Pulmonary Arterial Hypertension (PAH). At... View Details

Keywords: Pharmaceutical Companies; Technological And Scientific Innovation; Organ Donation; Health Care and Treatment; Health Disorders; Innovation and Invention; Growth and Development Strategy; Product Development; Pharmaceutical Industry; Pharmaceutical Industry; United States; District of Columbia

April 2017
Supplement

Imprimis (B)

By: Ramon Casadesus-Masanell, Karen Elterman and Marc Appel

This case is a supplement to Imprimis (A). It describes the company’s decision to enter into the pharmaceutical compounding business in 2013–2014. Imprimis purchased a compounded ophthalmological medication called Dropless Therapy, which was injected into patients’... View Details

Keywords: Healthcare; Drug Compounding; Drug Development; Pharmaceuticals; Small Business; Decision-making, Business Model; Mark Baum; Imprimis; Decision Making; Strategy; Health Care and Treatment; Policy; Pharmaceutical Industry; United States

August 2018
Article

The Impact of the Entry of Biosimilars: Evidence from Europe

By: Fiona M. Scott Morton, Ariel Dora Stern and Scott Stern

Biologics represent a substantial and growing share of the U.S. drug market. Traditional “small molecule” generics quickly erode the price and share of the branded product upon entry; however, only a few biosimilars have been approved in the U.S. since 2015, thereby... View Details

Keywords: Health Care; Biosimilars; Biologics; Pharmaceutical Competition; Healthcare Spending; Innovation; Health Care and Treatment; Spending; Market Entry and Exit; Competition; Innovation and Invention; Pharmaceutical Industry; United States; Europe

Find at Harvard

Register to Read

01 Mar 2007
News

Daniel Vasella

portfolio of product lines, setting Novartis apart from its global competitors. Although initially regarded by critics as too inexperienced to lead a multinational pharmaceutical company, Vasella has triumphed. Three years ago he was... View Details

Keywords: Roger Thompson; multinational pharmaceutical company; prescription drugs; vaccines; Medicare; generics business; Health, Social Assistance

September 2014
Supplement

Pfizer and AstraZeneca: Marketing an Acquisition (B)

By: John A. Quelch and James Weber

This (B) case provides a brief description of the outcome of the (A) case. View Details

Keywords: Health Care Policy; Pharmaceutical Sales; Mergers And Acquisitions; Marketing; Pharmaceutical Industry; United Kingdom; United States

November 2013
Case

GlaxoSmithKline in China (A)

By: John A. Quelch and Margaret L. Rodriguez

Four GlaxoSmithKline employees were accused of bribing Chinese health care workers to prescribe the company's drugs. The accusations brought to light the questionable incentive structures of the Chinese health care system and the pressure on companies to adhere to... View Details

November 2013 (Revised September 2015)
Supplement

GlaxoSmithKline in China (B)

By: John A. Quelch and Margaret L. Rodriguez

In 2013, Chinese investigators detained four GSK employees for allegedly bribing health care staff to sell GSK pharmaceuticals. A month later, GSK's Asia Pacific regional president, Abbas Hussain, said the company would help identify corrupt practices. Two days later,... View Details

November 2006
Case

Selling Biovail Short

By: Malcolm P. Baker, Chris Lombardi and Aldo Sesia

Hedge fund SAC Capital and analysts from Gradient Analytics and Banc of America face charges of stock price manipulation from Biovail, a Canadian pharmaceutical company. Gradient and BofA produced negative reports on Biovail's earnings quality. At the same time, SAC... View Details

Keywords: Stock Shares; Investment Banking; Asset Pricing; Financial Strategy; Crime and Corruption; Pharmaceutical Industry; Pharmaceutical Industry; Canada

October 2014 (Revised May 2017)
Teaching Note

Pfizer and AstraZeneca: Marketing an Acquisition (A) & (B)

By: John A. Quelch

Keywords: Mergers ＆ Acquisitions; Pharmaceutical Companies; Economic Impact Of Mergers; Mergers Impact On International Economies; Impact On Consumers Of Mergers; Customers; Economics; Marketing; Planning; Strategy; Pharmaceutical Industry; Europe; North and Central America

September 2014 (Revised February 2015)
Case

Pfizer and AstraZeneca: Marketing an Acquisition (A)

By: John A. Quelch and James Weber

In 2014, Pfizer proposed a friendly acquisition of AstraZeneca, but the AstraZeneca board resisted over price and strategy concerns. Was this good for pharmaceutical consumers? Pfizer, like pharmaceutical companies in general, faced difficulties in growing sales due to... View Details

Keywords: Health Care Policy; Mergers And Acquisitions; Marketing; Government Relations; Crisis Management; Decision Making; Growth and Development; Management; Markets; Strategy; Pharmaceutical Industry; United Kingdom; United States

October 1993 (Revised February 1995)
Case

Dendrite International

By: Frank V. Cespedes and Marie Bell

Dendrite International is a $23 million (1992 revenues) supplier of sales automation software to pharmaceuticals companies in Europe, Japan, and the United States. The firm's strategy has depended on being a full-service supplier to multinational firms. Impending... View Details

Keywords: Accounting Audits; Cost vs Benefits; Forecasting and Prediction; Marketing Strategy; Risk and Uncertainty; Sales; Competitive Advantage; Information Technology Industry; Japan; Europe; United States

October 2019
Supplement

Impax Laboratories: Executing Accretive Acquisitions (B)

By: Benjamin C. Esty and Daniel Fisher

Explores events after Impax announced the acquisition of a portfolio of generic pharmaceutical products from Teva in June 2016. View Details

Keywords: Financial Reporting; Financial Statements; Mergers and Acquisitions; Capital Structure; Financial Strategy; Competition; Competitive Advantage; Corporate Strategy; Pharmaceutical Industry; United States

11 May 2020
Op-Ed

Immigration Policies Threaten American Competitiveness

data (Miguelez and Fink, 2013), Figure 1 shows that America received more than half of migrating inventors from 2000-2010. Figure 1: Migration of inventors, 2000-2010 Immigrants can be found in times of success and times of crisis.... View Details

Keywords: by William R. Kerr

November 2010 (Revised December 2010)
Background Note

HR 3509

By: David F. Hawkins

HR 3509 ("2010 Health Reform Bill") imposition of a fee in pharmaceutical sales and an excise tax on medical device sales raises accounting issues. View Details

Keywords: Accounting; Governing Rules, Regulations, and Reforms; Government Legislation; Taxation; Pharmaceutical Industry; Pharmaceutical Industry; United States

Find at Harvard

January 2007 (Revised April 2011)
Case

Farmacias Similares: Private and Public Health Care for the Base of the Pyramid in Mexico

By: Michael Chu and Regina Garcia-Cuellar

Farmacias Similares, serving Mexico's low-income sector, grew to $600 million sales and 3,400 drugstores while deep reforms to help the poor swept the public health system. Adjacent to each store, for $2 per visit, medical clinics provided access to doctors for 2.3... View Details

Keywords: Private Sector; Public Sector; Health Care and Treatment; Growth and Development Strategy; Poverty; Pharmaceutical Industry; Pharmaceutical Industry; Mexico

December 1999 (Revised August 2001)
Case

Millennium Pharmaceuticals, Inc. (A)

By: Stefan H. Thomke and Ashok Nimgade

Focuses on Millennium's strategy to grow and revolutionize drug development through the use of new technologies such as genomics. Describes how Millennium Pharmaceuticals--a fast-growing biotechnology firm in Cambridge, MA--has used strategic alliances to finance the... View Details

Keywords: Cost Management; Financing and Loans; Medical Specialties; Retention; Growth and Development Strategy; Time Management; Product Development; Problems and Challenges; Alliances; Technology; Pharmaceutical Industry; Pharmaceutical Industry; Cambridge

February 2001
Background Note

National Innovation Systems and Comparative Industry Evolution

Discusses U.S. and Japanese innovation systems. Illustrates these with comparative studies of computer and pharmaceutical industries. Probes effects of labor, capital, and customer market institutions on these sectors in the United States and Japan. View Details

Keywords: Industry Growth; Innovation and Invention; Pharmaceutical Industry; Pharmaceutical Industry; Japan; United States